Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Corp.

www.bostonscientific.com

Latest From Boston Scientific Corp.

Global Approvals Analysis: Emerging Markets Drive Volume Of OUS Approvals

The numbers of medical device approvals were up in most regions outside the US and the biggest surge, by percentage, was in approvals from emerging markets and the so-called BRIC countries. It remains to be seen if the trend will continue in 2018, but many companies are already counting on important non-US approvals coming in the next year.

Approvals Innovation

Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific

Starts & Stops is a regular feature highlighting Medtech Insight's monthly picks of noteworthy clinical trial announcements, initiations, completions, and suspensions. The list for December is headlined by announcements on Edwards' transcatheter valve technologies. Meanwhile, MValve, a company Boston Scientific has invested in, is not going forward with a planned trial of its MValve dock device with Boston Scientific's Lotus valve, which is currently off the market.

Clinical Trials Starts & Stops

MRI And Cardiac-Rhythm Devices: A Match Made In Medicare

A proposed coverage policy from the US Centers for Medicare and Medicaid Services would not only cover magnetic resonance imaging for patients with an implanted cardiac rhythm management device with an FDA-approved indication for MRI-compatibility, but will also cover MRI in patients with devices without that FDA labeling in certain circumstances.

United States Clinical Trials

JPM2018: $15bn Market Opp Awaits Boston Scientific, Forecasts Mahoney

Boston Scientific CEO and chairman Mike Mahoney provided a positive preliminary Q4 earnings outlook during his presentation at the JP Morgan HealthCare Conference on Jan. 9, and outlined plans for the medical device giant's growth for 2018 and beyond, including a $15bn market opportunity between 2018 and 2021.

Sales & Earnings Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register